Pharmafile Logo

somapacitan

- PMLiVE

EMA starts review of Xtandi in non-metastatic prostate cancer

The evaluation is based on positive results from the PROSPER trial

Biogen Idec building

Biogen pays $590m for Pfizer cognition drug

Early stage studies look positive for schizophrenia drug

- PMLiVE

Novartis pushes ‘virtual’ clinical trial concept

Teams up with Science 37 to run ten digital-based trials over the next three years

- PMLiVE

Merck and Pfizer set to win NICE backing for Bavencio

The PD-L1 inhibitor is being assessed for the treatment of mMCC patients

- PMLiVE

Novo launches $165m antimicrobial resistance initiative

The REPAIR Fund will support groups looking to combat antibiotic resistance

translational pharmacology medicine dose

UK government updates the Model Clinical Trials Agreement

New regulation aims to speed-up R&D

- PMLiVE

Novo’s oral semaglutide ‘safe and well-tolerated’

Releases first phase III data on the new version of its diabetes treatment

- PMLiVE

Pfizer’s leukaemia drug Mylotarg backed for use in EU

The CHMP’s positive opinion could see the drug return to market after almost eight years

Products come and go, but a pharma company’s most valuable, durable asset is its reputation, writes Duncan Mackenzie-Reid and Simon Grist

Hiding between the lines of any company’s ledgers is an intangible asset, invisible to most auditors, but with the potential to have a very real impact on bottom line. Pharma...

Evoke Mind+Matter

- PMLiVE

AllTrials tracker site names clinical trial non-reporters

The FDAAA site seeks to highlight the failings of the FDA Amendments Act 2007

- PMLiVE

Merck/Pfizer’s cancer immunotherapy latecomer hits a snag

Bavencio fails a key lung cancer trial

- PMLiVE

J&J’s Erleada first US drug for non-metastatic prostate cancer

Drug approved by the FDA on the back of data from the SPARTAN study

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links